Found 34 articles for: "Janus kinase inhibitor"
Analysis of Reddit Reveals JAK Inhibitor Questions Among Atopic Dermatitis Patients
April 2024 | Volume 23 | Issue 4 | Editorials | e121 | Copyright © April 2024
Reddit is a popular social media website that is increasingly being used as a source of health information and discussion, especially among the younger population. We analyzed the subreddit "ecze...
Read MoreINDIVIDUAL ARTICLE: Atopic Dermatitis Skincare and Impact on Quality of Life for Patients with Skin of Color
March 2024 | Volume 23 | Issue 3 | Supplement Individual Articles | SF395747s6 | Copyright © March 2024
Atopic Dermatitis (AD) epidemiologic studies report a higher incidence and prevalence among populations with skin of color (SOC). Additionally, differences in AD underlying gene mutations and ski...
Read MoreNovel Clinical Applications of Topical Ruxolitinib: A Case Series
March 2024 | Volume 23 | Issue 3 | Case Reports | 188 | Copyright © March 2024
Topical ruxolitinib, a potent Janus kinase (JAK) inhibitor, has shown significant efficacy in treating inflammatory skin conditions. While its use has already been established in atopic dermatiti...
Read MoreTopical Calcineurin Inhibitors in the Management of Chronic Pruritus in Older Adults: A Research Letter
February 2024 | Volume 23 | Issue 2 | Editorials | e70 | Copyright © February 2024
In this study, we aimed to analyze the literature to date on the utilization of topical calcineurin inhibitors in the management of pruritus among older adults, ages 65 and older. The 16 stu...
Read MoreA Case Series of TNF Inhibitor-Induced Psoriasis Successfully Treated With Upadacitinib
February 2024 | Volume 23 | Issue 2 | Case Reports | e60 | Copyright © February 2024
Tumor necrosis factor-alpha inhibitors (TNF-i) are commonly used to treat immune-mediated diseases such as psoriasis, psoriatic arthritis (PsA), inflammatory bowel disease (IBD), spondyloarthriti...
Read MoreFactors Impacting New Drug Adoption in the Clinical Setting: A Survey of Dermatologists
January 2024 | Volume 23 | Issue 1 | Editorials | 1362 | Copyright © January 2024
Deucravacitinib for Moderate-to-Severe Psoriasis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
February 2024 | Volume 23 | Issue 2 | Original Article | 67 | Copyright © February 2024
There is contrasting evidence regarding the efficacy and safety of JAK (Janus kinase) inhibitors in the treatment of psoriasis. This systematic review and meta-analysis assessed deucravacitinib, ...
Read MoreOff-Label Use of Janus Kinase Inhibitors in Inflammatory Cutaneous Diseases
December 2023 | Volume 22 | Issue 12 | Original Article | 1183 | Copyright © December 2023
Dysregulation of Janus kinase (JAK) pathways from uncontrolled cytokine signaling comprises the pathological basis for many complex inflammatory cutaneous disorders. Oral JAK inhibitors, upadacit...
Read MoreINDIVIDUAL ARTICLE: Management of Prurigo Nodularis
December 2023 | Volume 22 | Issue 12 | Supplement Individual Articles | SF365502s15 | Copyright © December 2023
Background: Prurigo nodularis (PN) is a chronic disease characterized by intense pruritus and nodular lesions associated with reduced quality of life. Until recently, no US Food ...
Read MoreA Review of the Current Landscape of Hidradenitis Suppurativa Treatment Development
October 2023 | Volume 22 | Issue 10 | Original Article | 1021 | Copyright © October 2023
Background: Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition characterized by recurrent nodules and abscesses leading to subsequent scarring and tunnel form...
Read MoreOff-Label Use of Baricitinib in Dermatology
August 2023 | Volume 22 | Issue 8 | Original Article | 795 | Copyright © August 2023
The current US Food and Drug Administration (FDA) indications for baricitinib include alopecia areata, rheumatoid arthritis, and COVID-19. However, increasing evidence indicates that baricitinib ...
Read MoreWATCH VIDEO ABSTRACT: Scarring and Dyschromias in Fitzpatrick Skin Type IV-VI: A Review of Dermatologic Treatment Protocols
March 2023 | Volume 22 | Issue 3 | Original Article | 288 | Copyright © March 2023
Read MoreThe Safety and Efficacy of Roflumilast Cream 0.15% and 0.05% in Patients With Atopic Dermatitis: Randomized, Double-Blind, Phase 2 Proof of Concept Study
February 2023 | Volume 22 | Issue 2 | Original Article | 139 | Copyright © February 2023
Background: Patients with atopic dermatitis (AD) need safe and effective topical treatments.
Objective: To assess safety and efficacy of roflumilast cream in pa...
Read MoreScarring and Dyschromias in Fitzpatrick Skin Type IV-VI: A Review of Dermatologic Treatment Protocols
July 2023 | Volume 22 | Issue 7 | Original Article | 7253 | Copyright © July 2023
Importance: Managing chronic conditions is an essential aspect of dermatologic care, especially regarding the resolution of inflammatory dermatologic disease and recovery of skin lesi...
Read MoreOff-Label Uses of JAK Inhibitors in Dermatology
October 2022 | Volume 21 | Issue 10 | Features | 1143 | Copyright © October 2022
The Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway is a crucial component of immune function, and JAK inhibitors allow dermatologists to regulate this pathway in ce...
Read MoreJAK Inhibitor Safety Compared to Traditional Systemic Immunosuppressive Therapies
December 2022 | Volume 21 | Issue 12 | Original Article | 1298 | Copyright © December 2022
Dermatologists treating atopic dermatitis are interested in the safety profile of the recently available JAK inhibitors, upadacitinib and abrocitinib, especially after they received boxed safety warni...
Read MoreRefractory Alopecia Areata and Vitiligo Responding to Tofacitinib Monotherapy
December 2022 | Volume 21 | Issue 12 | Case Reports | 1366 | Copyright © December 2022
Background: In the last several years, oral tofacitinib has become an increasingly utilized off-label treatment option for immune-mediated skin conditions such as alopecia areata (AA)...
Read MoreA Potential Alternative Treatment for Vitiligo: An Observational Study on Tacrolimus 0.3% Lotion
December 2022 | Volume 21 | Issue 12 | Features | 1370 | Copyright © December 2022
Vitiligo is a complex multifactorial disorder of depigmentation affecting 0.5 to 2% of the world's population without specific gender or racial prevalence.1 Though no treatments are FDA app...
Read MoreA Retrospective Review of Tofacitinib in the Treatment of Refractory Dermatomyositis
October 2022 | Volume 21 | Issue 10 | Editorials | 1133 | Copyright © October 2022
Dermatomyositis (DM) is an autoimmune myopathy with characteristic dermatologic features.1 Tofacitinib is an immunomodulator with proven efficacy against numerous immune-mediated disorders,...
Read MoreNew Biologics and Oral Drugs in Treatment of Moderate to Severe Psoriasis
August 2022 | Volume 21 | Issue 8 | Original Article | 826 | Copyright © August 2022
Psoriasis is known to have no definitive cure, which is in common with other inflammatory disorders. Various treatment options are available, and they help in decreasing the disease activity and impro...
Read MoreMedia and other results for: "Janus kinase inhibitor"
© 2023 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
